首页> 外文期刊>International Journal of Pharmaceutics >Compression-coated tablets of glipizide using hydroxypropylcellulose for zero-order release: In vitro and in vivo evaluation
【24h】

Compression-coated tablets of glipizide using hydroxypropylcellulose for zero-order release: In vitro and in vivo evaluation

机译:使用羟丙基纤维素零级释放的格列吡嗪压缩包衣片剂:体内和体外评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Compression coating, which presents some advantages like short manufacturing process and non-solvent residue over liquid coating, has been introduced to the oral administration systems for decades. The purpose of this study was to design a zero-order release of compression-coated tablets using hydroxypropylcellulose (HPC) as the coating layer and glipizide which was solubilized by manufacturing the inclusion complex of β-cyclodextrin as a model drug. The effects of the weight ratio of drug and the viscosity of HPC on the release profile were investigated by "f2" factor with Glucotrol XL?. The uptake and erosion study, the correlation coefficient (R) and the exponent (n) were used as indicators to justify drug release mechanism. Bioavailability in vivo was determined by administering the compression-coated tablets to rabbits in contrast with Glucotrol XL ?. It was found that the formulation presented a well zero-order behavior at the weight ratio of drug 11:14 (core:layer) and the combination of HPC-L (8.0 mPa s) and HPC-M (350 mPa s) (8:9), with the "f 2" of 66.90. The mechanism for zero-order release of these compression-coated tablets was solvent penetration into the dosage form and drug dissolution from the erosion of the gelled HPC matrix. The parameter AUC 0-∞ of the compression coated tablets and the market tablets were 37,255.93 ± 1474.08 h ng/ml and 43265.40 ± 1015.28 h ng/ml, while the relative bioavailability was 87.66 ± 1.56%. These studies demonstrate that the designed compression-coated tablets may be a promising strategy for peroral controlled release delivery system of water-insoluble drugs.
机译:数十年来,压缩包衣比液体包衣具有制造过程短和无溶剂残留等优点,已被引入口服给药系统。这项研究的目的是设计使用羟丙基纤维素(HPC)作为涂层和格列吡嗪的零级释放压制片剂,格列吡嗪通过制造β-环糊精的包合物作为模型药物而被增溶。药物重量比和HPC粘度对释放曲线的影响是通过GlucotrolXLα的“ f2”因子进行研究的。吸收和侵蚀研究,相关系数(R)和指数(n)用作证明药物释放机理的指标。与GlucotrolXLα相反,通过对兔子施用压制包衣的片剂来确定其体内生物利用度。发现该制剂在药物11:14(核心:层)的重量比以及HPC-L(8.0 mPa s)和HPC-M(350 mPa s)的组合下表现出良好的零级行为(8 :9),“ f 2”为66.90。这些压缩包衣片剂零级释放的机制是溶剂渗透到剂型中以及由于胶凝的HPC基质的侵蚀而引起的药物溶解。压制包衣片剂和市售片剂的参数AUC0-∞为37,255.93±147.08h ng / ml和43265.40±1015.28h ng / ml,相对生物利用度为87.66±1.56%。这些研究表明,设计的压制片剂可能是水不溶性药物经口控释给药系统的有前途的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号